Oncopeptides to host Capital Markets Update featuring leading global experts in Multiple Myeloma

Stockholm, October 22, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) will host a Capital Markets Update on November 13, 2025, from 09:00 to 12:00 CET. The event will be broadcast live online from the Stockholm, offering shareholders and potential investors an in-depth look at the company’s strategic direction and its expanding role in the evolving treatment landscape for multiple myeloma and beyond.

The half-day program will feature presentations and discussions featuring a distinguished group of international experts, providing clinical, scientific, and market perspectives from Europe, Japan, and the U.S.

Highlights include:

• Prof. Dr. Sebastian Theurich, LMU University Hospital Munich – “Multiple Myeloma and the Unmet Medical Need.”
• Dr. María-Victoria Mateos, University of Salamanca – “Clinical reflections on real-world experience with Pepaxti.”
• Dr. Claudio Cerchione, IRST IRCCS Italy, and Prof. Dr. med. Klaus Fenchel, Germany – “Panel discussion on the European treatment landscape and real-world evidence.”
• Prof. Shinsuke Iida, Nagoya City University (Japan) – “The Japanese multiple myeloma landscape.”
• Prof. Paul G. Richardson, Dana-Farber Cancer Institute / Harvard Medical School (U.S.) – “The potential of the PDC platform in the U.S. market.”

The event will also feature presentations from Dr. Björn Odlander, Founder & Managing Partner of HealthCap and Oncopeptides CEO Sofia Heigis, providing insights into Oncopeptides’ business outlook, growth strategy, and investment case.

How to attend
The Capital Markets Update will be streamed live from Inderes studio in Stockholm and later available on-demand at www.oncopeptides.com.

To sign up, please follow this link.


 
Full agenda
The event will be held in English. All times in CET. Agenda subject to change.

09.00 – 09.03 | Welcome
Speaker: David Augustsson, Director of IR, Oncopeptides.

09.03-09.20 | Bringing Hope through Science
Speaker: Sofia Heigis, CEO, Oncopeptides.

09.20-09.30 | Owner’s perspective
Speaker: Dr. Björn Odlander, founder and managing partner, HealthCap.

09.30-9.55 | Keynote 1: Multiple myeloma and the unmet medical need
Speaker: Prof. Dr. Sebastian Theurich.
Description: An introduction to multiple myeloma and the treatment landscape, emphasizing the need for new treatments in the 4L+ stage.

9.55-10.00 | From Need to Treatment – A Clinician’s Reflection
Speaker: Dr. María‑Victoria Mateos.
Description: Dr. Mateos shares her perspective on the evolving treatment landscape and the clinical relevance of Pepaxti in addressing unmet needs in relapsed and refractory multiple myeloma.

10.00-10.25 | Conversation: Relapsed, refractory multiple myeloma – clinical experience with Pepaxti
Speakers: Dr. Claudio Cerchione, Prof. Dr. med. Klaus Fenchel.
Description: A conversation on the European multiple myeloma landscape and the treatment challenges facing today´s healthcare practitioners.

10.25-10.35 | BREAK

10.35-10.45 | Keynote 2: The Japanese Multiple Myeloma landscape
Speaker: Prof. Shinsuke Iida.

10.45-10.55 | Keynote 3: The potential of the PDC platform in the U.S.
Speaker: Prof. Paul Richardson.

10.55-11.30 | Oncopeptides as an investment case – where do we go from here?
Speaker: Sofia Heigis, CEO, Oncopeptides.

11.30-11.45 | Questions and Answers from investors
All in-person participants.

11.45-11.50 | Closing remarks
Speaker: Sofia Heigis, CEO, Oncopeptides.

For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68

About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. 

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com